Recent Publications and Papers
Recent Publications and Papers
Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005; 61 (4):1216-26.
Chen B, Pogue BW, Zhou X, O’Hara JA, Solban N, Demidenko E, Hoopes PJ, Hasan T. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005; 11(2):720-7.
Savellano M, Hasan T. Photochemical targeting of epidermal growth factor receptor: a mechanistic study. Clin Cancer Res 2005; 11(4):1658-68.
Del Carmen MG, Rizvi I, Moor ACE, Oliva E, Chang Y, Sherwood M, Pogue B, Hasan T. Epidermal growth factor receptor targeted immunotherapy is synergistic with photodynamic treatment of ovarian cancer in vivo. J Nat Cancer Inst 2005;97(20), October 19, 2005.
O’Riordan K, Akilov O, Hasan T. The potential for photodynamic therapy in the treatment of localized infections. Photodiagnosis and Photodynamic Therapy 2005; (accepted).
Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatinine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 2005; 96:77-83.
Duska L, Berkowitz RS, Matulonis U, Muto MG, Goodman AK, McIntyre J, Klein A, Atkinson T, Seiden MV. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-met Hu G-CSF) support followed by radiotherapy in patients with “high risk” endometrial cancer. Gynecol Oncol 2005; 96:198-203.
Wenzel L, Dogan Ates A, Habbal R, Berkowitz RS, Goldstein DP, Bernstein M, Kluhsman BC, Osann K, Newlands E, Seckl MJ, Hancock B, Cella D. Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Mongr 2005; 34:94-8.
Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz RS, Aziz N. Quality of life in long-term cervical cancer survivors. Gynecol Oncol 2005; 97:310-317.
Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch, WR, Vitonis AF, Berkowitz RS, Finn OJ. Conditions that favor elicitation of immunity against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidem Biomarkers Prevention 2005; 14:1125-31.
Wolfberg A, Berkowitz, RS, Goldstein DP, Feltmate C, Lieberman E. “Post-evacuation hCG levels predict risk of persistent gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol 2005; 106:548-552.
Bendikson K, Cramer, DW, Vitonis A, Hornstein MD. Ethnic background and in vitro fertilization outcomes. International Journal of Gynecology & Obstetrics, 2005. 88(3): p. 342-346.
Terry KL, DeVivo I, Titus-Ernstoff L, Sluss PM, Sluss, PM, Cramer, DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol, 2005;161(5):442-51.
Cramer DW, Titus-Ernstoff L, McKolonis JR, Welch WF, Vitonis AF, Berkowitz RS, Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2005;14(5):1125-1131.
Terry KL, DeVivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res, 2005;65(13):5974-5981.
Terry KL, Devivo I, Titus-Ernstoff L, Cramer DW. Progesterone receptor polymorphisms and ovarian cancer. American Association for Cancer Research 95th Annual Meeting 2004;305. Poster Sessions Abstract # 4509.
Drapkin R*, Lin Y, Horsten HH, Welch WR, Crum CP, Mok SC, Hecht JH. Human Epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research 2005, 65: 2162-2169. * corresponding author
Kanellopoulou C, Muljo SA, Kung AL, Ganesam S, Drapkin R, Jenuwein T, Livingston DM. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev 2005, 19: 489-501.
Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. cDNA array analysis of paclitaxel resistance. Description of paclitaxel resistance associated genes in ovarian and breast cancer cell lines. Cancer, Chemotherapy, and Pharmacology. 2005; 55: 277-85.
Duan Z, Rosemary Foster R, Brakora KA, Rushdia Z. Yusuf RZ, Seiden MV. GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer, Chemotherapy, and Pharmacology. 2005; 19:1-9.
Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul PK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H. A Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer. J Clin Oncol. 2005;23:5597-604.
Penson, RT, Seiden, MV, Matulonis UA, Appleman LJ, Fuller, AF, Goodman, AK, Campos SM, Clark JW, Roche M, Eder, JP. A Phase I Clinical Trial of Continual Alternating Etoposide and Topotecan in Refractory Solid Tumors. Brit J of Canc, 2005 93:54-59.
Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Mok SC. Identification of over-expression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res, 2005, 11,6880-6888.
Feltmate CM, Lee RL, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole genome allelotyping identified distinct loss of heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res, 2005, In press
Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res, 2005, in press.
Newsworthy lectures/slides, and other timely content of interest to members and visitors to the program.
The Journal of the National Cancer Institute has selected the Marcela del Carmen, et al., article “Epidermal growth factor receptor targeted immunotherapy is synergistic with photodynamic treatment of ovarian cancer in vivo” for editorial discussion, media release, and for “In this Issue” mention. (Del Carmen MG, Rizvi I, Moor ACE, Oliva E, Chang Y, Sherwood M, Pogue B, Hasan T. Epidermal growth factor receptor targeted immunotherapy is synergistic with photodynamic treatment of ovarian cancer in vivo. J Nat Cancer Inst 2005;97 (20), October 19, 2005.
DF/HCC physicians well represented at Annual Ovarian Cancer National Alliance (OCNA) Conference. Drs. Seiden, Penson, Duska, and Goodman all presented new information and met with leaders of the advocacy community in Atlanta at the annual Fall OCNA conference.